Next-Generation Drug Conjugates (NDCs) Market Size, Share & Trends Analysis Report By Product Type, By Application, By End-User, By Region And Segment Forecasts 2026 – 2035

Next-Generation Drug Conjugates (NDCs) Market By Product Type (Peptide Drug Conjugates, Oligonucleotide-Drug Conjugates, RNAi Conjugates, GalNAc-siRNA Conjugates, Small Molecule-Drug Conjugates, Peptide Radionuclide Conjugates, Antisense Oligonucleotide Conjugates, Ligand-Mediated RNAi Conjugates, Hybrid Conjugates, and Others), By Application (Oncology, Rare Genetic Disorders, Metabolic Diseases, Neurodegenerative Diseases, Cardiovascular Diseases, Autoimmune Disorders, Infectious Diseases, Respiratory Diseases, Genetic Disorders, and Others), By End-User (Biopharmaceutical Companies, Academic & Research Institutes, Contract Research Organizations, Hospitals & Clinics, Contract Manufacturing Organizations, Government Research Agencies, Specialty Clinics, Diagnostic Laboratories, Pharmaceutical Distributors, and Others), and By Region: Global Industry Analysis, Trends, Size, Key Companies, Regional Outlook, Forecast 2026 - 2035